Physician profile
Michael Mooreville
NPI 1619989696
$1,239.77
in general payments reported to CMS, 2019-2025
15 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $153 · 2021: $120 · 2022: $129 · 2023: $169 · 2024: $156 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.55 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $327.29 | 2022-2025 | Erleada |
| Pfizer INC. | $215.29 | 2019-2021 | |
| Astellas Pharma US INC | $210.63 | 2019-2024 | Myrbetriq |
| C. R. Bard, INC. & Subsidiaries | $84.68 | 2019 | |
| Tolmar, INC. | $80.06 | 2023-2025 | Jatenzo, Eligard |
| Abbvie INC. | $63.35 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $46.24 | 2025 | Erleada |
| Urogen Pharma, INC. | $41.51 | 2022-2025 | |
| 180 Medical, INC. | $37.75 | 2020-2023 | |
| Clarus Therapeutics INC. | $29.46 | 2021 | |
| Convatec INC. | $29.40 | 2022 | |
| Laborie Medical Technologies Corp. | $24.30 | 2025 | |
| Urovant Sciences INC | $23.44 | 2022 | |
| Allergan, INC. | $14.13 | 2019 | |
| Boston Scientific Corporation | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mooreville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.